Zachary Crees, MD
Medical Oncology · Saint Louis, MONPI 1225419344
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,523 of the $27,391 with a category attached, or 93.2%. 15 manufacturers reported payments, led by Gamida Cell Inc. at 43.3% of the total. 2025 is the largest year on record at $17,443, more than ten times the $252 reported in 2019.
Across 40 payments — averaging $684.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gamida Cell Inc.$12K
- Biolinerx USA, Inc.$9K
- Vertex$5K
- Taiho Oncology, Inc.$427
- Johnson & Johnson$211
- Astellas Pharma Global Development$194
- plus $926 from 9 others
Across 11 payments — averaging $22,644 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$249K
What the payments were for
- Consulting fees$25,52393%
- Speaking & faculty fees$2721%
- Travel & lodging$2711%
- Food & beverage$6102%
- Education$7163%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gamida Cell Inc. | 7 | $11,866 |
| Biolinerx USA, Inc. | 3 | $9,000 |
| Vertex | 2 | $4,767 |
| Taiho Oncology, Inc. | 4 | $427 |
| Johnson & Johnson | 2 | $211 |
| Astellas Pharma Global Development | 1 | $194 |
| Genentech USA, Inc. | 2 | $185 |
| Lilly USA, LLC | 12 | $167 |
| AstraZeneca | 1 | $115 |
| Incyte Corporation | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $99 |
| Astellas Pharma US Inc | 1 | $95 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Geron Corporation | 1 | $67 |
| Bristol Myers Squibb | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,391 in reported general payments places this provider in the 75th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 64 | $847,343 |
| XospataGilteritinib Fumarate | 36 | $606,005 |
| RezurockBelumosudil Mesylate | 26 | $446,749 |
| BrukinsaZanubrutinib | 23 | $341,311 |
| IclusigPonatinib Hcl | 12 | $259,945 |
| PromactaEltrombopag Olamine | 12 | $237,244 |
| VenclextaVenetoclax | 55 | $156,236 |
| CresembaIsavuconazonium Sulfate | 24 | $144,597 |
| RevlimidLenalidomide | 11 | $134,560 |
| Imatinib Mesylate | 82 | $53,285 |
| EliquisApixaban | 16 | $12,754 |
| ValacyclovirValacyclovir Hcl | 183 | $6,095 |
| Sirolimus | 20 | $5,525 |
| Fluconazole | 81 | $4,216 |
| Ciprofloxacin Hcl | 124 | $3,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $100 | $847,34364 claims |
| Astellas Pharma US IncXospata, Cresemba | $95 | $750,60260 claims |
| Sanofi-aventis U.S. LLCRezurock | $75 | $446,74926 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $99 | $259,94512 claims |
| Bristol Myers SquibbRevlimid | $23 | $134,56011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 144 medical oncology providers in Missouri.
Other medical oncology in Saint Louis
- Brad KahlSaint Louis$336K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Milan ChhedaSaint Louis$105K
- Maurice WillisSaint Louis$101K
- Moh'd KhushmanSaint Louis$84K
- Camille AbboudSaint Louis$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.